Why the study?
What are the pharmacotherapy options for treating venous thromboembolism in cancer patients?
Population
Cancer patients with venous thromboembolism (VTE)
Design
Review
Authors
Loading...
LMWHs should remain preferred for cancer-associated VTE; leaves open routine use of novel oral anticoagulants pending further trials.
What are the pharmacotherapy options for treating venous thromboembolism in cancer patients?
LMWHs remain the cornerstone of VTE treatment in cancer patients, while novel oral anticoagulants need further investigation before routine use.
Prandoni et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: